-
充血性心力衰竭是一种因心脏无法泵出身体代谢所需要的足够血液的临床综合征, 临床上常将其分为收缩性和舒张性心力衰竭两类。许多因素可以导致心力衰竭, 其中冠心病和心肌病是两个常见原因。核心脏病学显像技术是一类无创性的检查方法, 对临床医生在无创条件下推断出心力衰竭的潜在原因具有重要意义。研究表明, 相当一部分有症状的心力衰竭患者存在相对正常的左室射血分数(left ventricular ejevtion fraction, LVEF)[1]。收缩功能正常的心脏病患者其发病和死因往往是心力衰竭。心脏舒张功能受心肌舒张情况、心室充盈情况和室壁弹性情况的共同影响, 患有心肌缺血、高血压或心肌病时, 用核医学设备判断舒张功能是否异常可以在早期评判心肌受累情况。目前, 门控SPECT心肌灌注显像已经常规地应用于心肌缺血的诊断中, 包括定量门控SPECT心肌灌注显像、交感神经显像和心肌代谢显像等在内的核心脏病学检查方法非常适用于长期随访中观察心肌的变化情况[2]。本文旨在介绍应用核医学检查方法测定患者的心脏功能, 对患者的心肌功能进行风险评估, 并概述核心脏病学及心脏生理学的发展。
核心脏病学在心力衰竭中的临床应用
Clinical use of nuclear cardiology in the assessment of heart failure
-
摘要: 核心脏病学的显像技术是一种常用的无创的诊断心力衰竭的重要手段,在评估心力衰竭程度和指导心力衰竭治疗方面发挥了重要作用。定量门控SPECT心肌灌注显像借助其定量分析软件,可以定量评价心脏容积、左心室射血分数、每搏输出量、心脏舒张功能。静息和(或)负荷心肌灌注显像不仅能鉴别非缺血性心力衰竭和缺血性心力衰竭,而且能判别心肌是否存在活性。核心脏病显像技术能轻易地鉴别出舒张性心力衰竭(也称为射血分数正常的心力衰竭),它通过高峰充盈率和高峰充盈率时间可以准确地评估舒张性心力衰竭的程度。借助三维成像等新技术定量门控SPECT能有效评估左室运动情况,评估室壁厚度对其是一个很好的补充。心肌灌注显像还常用于判别患者是否适合植入心脏除颤器及是否适合进行心脏再同步化治疗。123I-间碘苄胍神经递质显像能为心力衰竭患者提供预后信息。心肌代谢活动与其功能密切相关,能量代谢底物是评价药物治疗是否有助于提高心力衰竭患者心功能的一个指标,123I-15-(p-碘苯基)3-R, S-甲基十五烷酸是一种临床研究中常用的心肌代谢显像示踪剂。借助新示踪剂的应用,包括神经递质显像和心肌代谢显像在内的核心脏病学显像技术常用来完善心力衰竭的诊断。核心脏病学显像技术在诊断心力衰竭及指导临床治疗方面做出了巨大贡献。Abstract: Nuclear cardiology is the most commonly performed non-invasive cardiac imaging test in patients with heart failure, and it plays an important role in their assessment and management.Quantitative gated single positron emission computed tomography is used to assess quantitatively cardiac volume, left ventricular ejection fraction, stroke volume, and cardiac diastolic function.Resting and stress myocardial perfu-sion imaging can not only identify nonischemic heart failure and ischemic heart failure, but aslo demonstrat myocardial viability.Diastolic heart failure aslo termed as heart failure with a preserved left ventricular ejection fraction is readily identified by nuclear cardiology techniques and can accurately be estimated by peak filling rate and time to peak filling rate.With newer techniques such as three-dimensional, quantitative gated single positron emission computed tomography can assess movement of the left ventricle, and wall thickening evaluation aids its assessment.Myocardial perfusion imaging is also commonly used to identify candidates for implantable cardiac defibrillator and cardiac resynchronization therapies.Neurotransmitter imaging using 123I-metaiodobenzylguanidine offers prognostic information in patients with heart failure. Metabolism and function in the heart are closely related, and energy substrate metabolism is a potential target of medical therapies to improve cardiac function in patients with heart failure.Cardiac metabolic imaging using 123I-15-(p-iodophenyl)3-R, S-methylpentadecacoic acid is a commonly used tracer in clinical studies to diagnose metabolic heart failure.Nuclear cardiology tests, including neurotransmitter imaging and metabolic imaging, are now easily preformed with new tracers to improve heart failure diagnosis.Nuclear cardiology techniques contribute significantly to identifying patients with heart failure and to guiding their management decisions.
-
[1] Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence andoutcome of heart failure with preserved ejection fraction. N Engl J Med, 2006, 355(3): 251-259. doi: 10.1056/NEJMoa052256 [2] Matsuo S, Nakae I, Tsutamoto T, et al. A novel clinical indicator using Tc-99m sestamibi for evaluating cardiac mitochondrial function in patients with cardiomyopathies. J Nucl Cardiol, 2007, 14(2): 215-220. doi: 10.1016/j.nuclcard.2006.10.022 [3] Matsuo S, Matsumoto T, Nakae I, et al. Prognostic value of ECG-gated thallium-201 single-photon emission tomography in patients with coronary artery disease. Ann Nucl Med, 2004, 18(7): 617-622. doi: 10.1007/BF02984584 [4] Germano G, Kavanagh PB, Slomka PJ, et al. Quantitation in gated perfusion SPECT imaging: the Cedars-Sinai approach. J Nucl Cardiol, 2007, 14(4): 433-454. doi: 10.1016/j.nuclcard.2007.06.008 [5] Matsuo S, Nakamura Y, Takahashi M, et al. Effect of red wine and ethanol on production of nitric oxide in healthy subjects. Am J Cardiol, 2001, 87(8): 1029-1031. doi: 10.1016/S0002-9149(01)01446-1 [6] Matsuo S, Matsumoto T, Takashima H, et al. The relationship between flow-mediated brachial artery vasodilation and coronary vasomotor responses to bradykinin: comparison with those to acetylcholine. J Cardiovasc Pharmacol, 2004, 44(2): 164-170. doi: 10.1097/00005344-200408000-00004 [7] Sciagrà R, Berti V, Genovese S, et al. Reliability of myocardial perfusion gated SPECT for the reproducible evaluation of resting left ventricular functional parameters in long-term follow-up. Eur J Nucl Med Mol Imaging, 2010, 37(9): 1722-1729. doi: 10.1007/s00259-010-1444-y [8] Matsuo S, Sato Y, Nakae I, et al. Evaluation of cardiac resynchronization therapy in drugresistant dilated-phase hyper-trophic cardiomyopathy by means of Tc-99m sestamibi ECG-gated SPECT. Ann Nucl Med, 2006, 20(9): 643-647. doi: 10.1007/BF02984664 [9] Nakajima K, Matsuo S, Kawano M, et al. The validity of multicenter common normal database for identifying myocardial ischemia: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med, 2010, 24(2): 99-105. doi: 10.1007/s12149-009-0331-8 [10] Matsuo S, Nakajima K, Horie M, et al. Prognostic value of normal stress myocardial perfusion imaging in Japanese population. Circ J, 2008, 72(4): 611-617. [11] Akhter N, Nakajima K, Okuda K, et al. Regional wall thickening in gated myocardial perfusion SPECT in a Japanese population: effect of sex, radiotracer, rotation angles and frame rates. Eur J Nucl Med Mol Imaging, 2008, 35(9): 1608-1615. doi: 10.1007/s00259-008-0804-3 [12] NakajimaK, NishimuraT. Inter-institution preference-based variability of ejection fraction and volumes using quantitative gated 99mTc-tetrofosmin: a multicentre study involving 106 hospitals. Eur J Nucl Med Mol Imaging, 2006, 33(2): 127-133. doi: 10.1007/s00259-005-1916-7 [13] Johnson LL, Verdesca SA, Aude WY, et al. Postischemic stunning can affect left ventricular ejection fraction and regional wall motion on post-stress gated sestamibi tomograms. J Am Coll Cardiol, 1997, 30(7): 1641-1648. doi: 10.1016/S0735-1097(97)00388-4 [14] Nishimura T, Nakajima K, Kusuoka H, et al. Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT: J-ACCESS study. Eur J Nucl Med Mol Imaging, 2008, 35(2): 319-328. doi: 10.1007/s00259-007-0608-x [15] Matsuo S, Nakajima K, Yamasaki Y, et al. Prognostic value of normal stress myocardial perfusion imaging and ventricular function in Japanese asymptomatic patients with type 2 diabetes—a study based on the J-ACCESS-2 database. Circ J, 2010, 74(9): 1916-1921. doi: 10.1253/circj.CJ-10-0098 [16] Shaw LJ, Hachamovitch R, Berman DS, et al. The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia. Economics of Noninvasive Diagnosis (END) Multicenter Study Group. J Am Coll Cardiol, 1999, 33(3): 661-669. doi: 10.1016/S0735-1097(98)00606-8 [17] Nakajima K, Yamasaki Y, Kusuoka H, et al. Cardiovascular events in Japanese asymptomatic patients with type 2 diabetes: a 1-year interim report of a J-ACCESS 2 investigation using myocardial perfusion imaging. Eur J Nucl Med Mol Imaging, 2009, 36(12): 2049-2057. doi: 10.1007/s00259-009-1207-9 [18] Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation, 1998, 97(6): 535-543. doi: 10.1161/01.CIR.97.6.535 [19] Piccini JP, Horton JR, Shaw LK, et al. Single-photon emission computed tomography myocardial perfusion defects are associated with an increased risk of all-ause death, cardiovascular death, and sudden cardiac death. Circ Cardiovasc Imaging, 2008, 1(3): 180-188. doi: 10.1161/CIRCIMAGING.108.776484 [20] Iskandrian AS, Hakki AH, Kane SA, et al. Rest and redistribution thallium-201 myocardial scintigraphy to predict improvement in left ventricular function after coronary arterial bypass grafting. Am Jcardiol, 1983, 51(8): 1312-1316. doi: 10.1016/0002-9149(83)90304-1 [21] Haque T, Furukawa T, Yoshida S, et al. Echocardiography and fatty acid single photon emission tomography in predicting reversibility of regional left ventricular dysfunction after coronary angioplasty. Eur Heart J, 1998, 19(2): 332-341. doi: 10.1053/euhj.1997.0734 [22] Pavlovic SV, Sobic-Saranovic DP, Beleslin BD, et al. One-year follow-up of myocardial perfusion and function evaluated by gated SPECT MIBI in patients with earlier myocardial infarction and chronic total occlusion. Nucl Med Commun, 2009, 30(1): 68-75. doi: 10.1097/MNM.0b013e32831a40dd [23] Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a metaanalysis. J Am Coll Cardiol, 2002, 39(7): 1151-1158. doi: 10.1016/S0735-1097(02)01726-6 [24] Korosoglou G, Lehrke S, Wochele A, et al. Strain-encoded CMR for the detection of inducible ischemia during intermediate stress. JACC Cardiovasc Imaging, 2010, 3(4): 361-371. doi: 10.1016/j.jcmg.2009.11.015 [25] Nagamachi S, Wakamatsu H, Fujita S, et al. Assessment of diastolic function using 16-frame 201Tl gated myocardial perfusion SPECT: a comparative study of QGS2 and pFAST2. Ann Nucl Med, 2008, 22(2): 115-122. doi: 10.1007/s12149-007-0091-2 [26] Nakae I, Matsuo S, Tsutamoto T, et al. Assessment of cardiacfunction in patients with heart disease by quantitative gated myocardialperfusionSPECT. AnnNuclMed, 2007, 21(6): 315-323. [27] Akincioglu C, Berman DS, Nishina H, et al. Assessment of diastolic function using 16-frame 99mTc-sestamibi gated myocardial perfusion SPECT: normal values. J Nucl Med, 2005, 46(7): 1102-1108. [28] Matsuo S, Nakamura Y, Tsutamoto T, et al. Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol, 2002, 9(4): 407-412. doi: 10.1067/mnc.2002.122765 [29] Matsuo S, Takahashi M, Nakamura Y, et al. Evaluation of cardiac sympathetic innervation with iodine-123-metaiodobenzyl-guanidine imaging in silent myocardial ischemia. J Nucl Med, 1996, 37(5): 712-717. [30] Matsuo S, Nakajima K, Okuda K, et al. Standardization of the heart-to-mediastinum ratio of 123I-labelled-metaiodobenzylguanidine uptake using the dual energy window method: feasibility of correction with different camera-collimator combinations. Eur J Nucl Med Mol Imaging, 2009, 36(4): 560-566. doi: 10.1007/s00259-008-0971-2 [31] Matsuo S, Nakae I, Masuda D, et al. Dilated cardiomyopathy relieved as a result of beta-blocker therapy: a case report—key points in assessment of prognosis based on MIBG myocardial scintigraphyandBNPlevels. AnnNuclMed, 2005, 19(3): 243-246. [32] Yamazaki J, Muto H, Kabano T, et al. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy—Clinical meaning of iodine 123-metaiodo-benzylguanidine myocardial single-photon emission computed tomography. AmHeartJ, 2001, 141(4): 645-652. [33] Nishioka SA, Martinelli Filho M, Brändao SC, et al. Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123I-MIBG myocardial scintigraphy. J Nucl Cardiol, 2007, 14(6): 852-859. doi: 10.1016/j.nuclcard.2007.08.004 [34] Matsuo S, Matsumoto T, Nakae I, et al. Evaluation of cardiac resynchronization therapy in drug-resistant idiopathic dilated cardiomyopathy by means of technetium-99m tetrofosmin electrocar-diography-gated single-photon emission computed tomography. Exp Clin Cardiol, 2004, 9(4): 248-250. [35] Matsuo S, Nakamura Y, Matsumoto T, et al. Prognostic value of iodine-123 metaiodobenzylguanidine imaging in patients with heart failure. Exp Clin Cardiol, 2003, 8(2): 95-98. [36] Nakata T, Wakabayashi T, Kyuma M, et al. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of aiotensin-converting enzyme inhibitors and/or beta-adreno-ceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging, 2005, 32(2): 186-194. doi: 10.1007/s00259-004-1624-8 [37] Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF(AdreView Myocardial Imaging for Risk Evaluation in Heart Failure)study. J Am Coll Cardiol, 2010, 55(20): 2212-2221. [38] Kawamoto M, Tamaki N, Yonekura Y, et al. Combined study with I-123 fatty acid and thallium-201 to assess ischemic myocardium: comparison with thallium redistribution and glucose metabolism. Ann Nucl Med, 1994, 8(1): 47-54. doi: 10.1007/BF03164986 [39] Matsuo S, Nakamura Y, Takahashi M, et al. Myocardial metabolic abnormalities in hypertrophic cardiomyopathy assessed by iodine-123-labeled beta-methyl-branched fatty acid myocardial scintigraphy and its relation to exercise-induced ischemia. Jpn Circ J, 1998, 62(3): 167-172. doi: 10.1253/jcj.62.167 [40] Ishida Y, Yasumura Y, Nagaya N, et al. Myocardial imaging with 1 2 3 I-BMIPP in patients with congestive heart failure. Int J Card Imaging, 1999, 15(1): 71-77. doi: 10.1023/A:1006152804670 [41] Yazaki Y, Isobe M, Takahashi W, et al. Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart, 1999, 81(2): 153-159. doi: 10.1136/hrt.81.2.153 [42] Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol, 2010, 56(11): 875-887. doi: 10.1016/j.jacc.2010.05.007 [43] Chang GY, Xie X, Wu JC. Overview of stem cells and imaging modalities for cardiovascular diseases. J Nucl Cardiol, 2006, 13(4): 554-569. doi: 10.1016/j.nuclcard.2006.05.012 [44] Matsuo S, Nakae I, Masuda D, et al. Scintigraphic evaluation of cardiac metabolism and sympathetic nerve function in alcoholic cardiomyopathy. Intern Med, 2006, 45(7): 465-467. doi: 10.2169/internalmedicine.45.1696 [45] Matsuo S, Nakae I, Takada M, et al. Noninvasive identification of myocardial sympathetic and metabolic abnormalities in a patient with restrictive cardiomyopathy—in comparison with perfusion imaging. Ann Nucl Med, 2002, 16(8): 569-572. doi: 10.1007/BF02988635 [46] Wichter T, Hindricks G, Lerch H, et al. Regional myocardial sympathetic dysinnervation in arrhythmogenic right ventricular cardiomyopathy. An analysis using 123I-meta-iodobenzylguanidine scintigraphy. Circulation, 1994, 89(2): 667-683. [47] Akashi YJ, Nakazawa K, Sakakibara M, et al. 123I-MIBG myocardial scintigraphy in patients with"takotsubo"cardiomyopathy. J Nucl Med, 2004, 45(7): 1121-1127. [48] Matsuo S, Nakamura Y, Takahashi M, et al. Cardiac sympathetic dysfunction in an athlete's heart detected by 123I-metaiodobenzylguanidine scintigraphy. Jpn Circ J, 2001, 65(5): 371-374. doi: 10.1253/jcj.65.371
计量
- 文章访问数: 1771
- HTML全文浏览量: 633
- PDF下载量: 4